Impact Biomedical: Submission Of Matters To A Vote Of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On November 5, 2025, Impact Biomedical Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). A total of 64,328,010 shares of common stock of the Company, representing 88.50% of the aggregate shares outstanding and eligible to vote on September 8, 2025, the record date for the Meeting, and constituting a quorum, were represented in person or by valid proxies at the Meeting. The stockholders approved the election of Frank D. Heuszel; Elise Brownell; Melissa Sims; Castel Hibbert; David Keene; Christian Zimmerman; Jason Grady and Chan Heng Fai Ambrose to serve as directors of the Company until the next Annual Meeting of the shareholders. The stockholders ratified the appointment of Grassi & Co. Certified Public Accountants, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The stockholders approved, on an advisory basis, the compensation of the named executive officers. The final voting results on these matters were as follows: 1. Approval of the election of Frank D. Heuszel; Elise Brownell; Melissa Sims; Castel Hibbert; David Keene; Christian Zimmerman; Jason Grady and Chan Heng Fai Ambrose to serve as directors of the Company until the next Annual Meeting of the shareholders: FOR AGAINST WITHHELD BROKER NON-VOTES Frank D. Heuszel 61,565,626 54,136 5,487 2,702,761 Elise Brownell 61,535,306 74,945 14,997 2,702,761 Melissa Sims 61,496,912 112,291 16,046 2,702,761 Castell Hibbert 61,564,380 45,380 15,489 2,702,761 David Keene 61,536,534 73,768 14,947 2,702,761 Christian Zimmerman 61,566,321 43,460 15,468 2,702,761 Jason Grady 61,566,251 52,677 6,321 2,702,761 Chan Heng Fai Ambrose 61,505,698 113,631 5,920 2,702,761 2. Ratification of the appointment of Grassi & Co. Certified Public Accountants, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025: FOR AGAINST ABSTAIN 64,126,924 174,317 26,769 3. Approval on an advisory basis of the compensation of the named executive officers: FOR AGAINST ABSTAIN BROKER NON-VOTES 61,512,770 107,684 4,795 2,702,761 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. IMPACT BIOMEDICAL INC. Date: November 6, 2025 By: /s/ Frank D. Heuszel Name: Frank D. Heuszel Title: Chief Executive Officer

Impact Biomedical: Submission Of Matters To A Vote Of Security Holders

Şirketle ilgili diğer haberler